Neurocrine Biosciences Stock Performance
| NBIX Stock | USD 142.00 1.11 0.79% |
On a scale of 0 to 100, Neurocrine Biosciences holds a performance score of 9. The company secures a Beta (Market Risk) of 1.1, which conveys a somewhat significant risk relative to the market. Neurocrine Biosciences returns are very sensitive to returns on the market. As the market goes up or down, Neurocrine Biosciences is expected to follow. Please check Neurocrine Biosciences' sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to make a quick decision on whether Neurocrine Biosciences' current price movements will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Neurocrine Biosciences are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain forward indicators, Neurocrine Biosciences showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.79 | Five Day Return (2.95) | Year To Date Return 3 | Ten Year Return 301.81 | All Time Return 1 K |
Ex Dividend Date 1995-12-29 |
1 | Neurocrine Biosciences, Inc. Shares Purchased by Mediolanum International Funds Ltd | 07/28/2025 |
2 | Neurocrine Q2 Revenue Jumps 17 | 08/01/2025 |
3 | Disposition of 106322 shares by Kevin Gorman of Neurocrine Biosciences at 35.99 subject to Rule 16b-3 | 08/07/2025 |
4 | Disposition of 1447 shares by Jude Onyia of Neurocrine Biosciences at 116.7471 subject to Rule 16b-3 | 08/26/2025 |
5 | Disposition of 1470 shares by Jude Onyia of Neurocrine Biosciences subject to Rule 16b-3 | 09/03/2025 |
6 | Neurocrine Biosciences, Inc. Receives Consensus Rating of Moderate Buy from Analysts | 09/04/2025 |
7 | Neurocrine price target raised by 5 at RBC Capital, heres why NBIX | 09/05/2025 |
8 | Teza Capital Management LLC Sells 12,560 Shares of Neurocrine Biosciences, Inc. NBIX | 09/08/2025 |
9 | Parkman Healthcare Partners LLC Buys 52,655 Shares of Neurocrine Biosciences, Inc. NBIX - MarketBeat | 09/11/2025 |
10 | Central Pacific Bank Trust Division Has 217,000 Position in Neurocrine Biosciences, Inc. NBIX | 09/15/2025 |
11 | Aug Spikes Does Neurocrine Biosciences Inc have pricing power - Market Weekly Review Risk Controlled Stock Pick Alerts - | 09/18/2025 |
12 | Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder | 09/22/2025 |
13 | Neurocrines ingrezza shows efficacy in tardive dyskinesia NBIX | 09/23/2025 |
14 | GRFS or NBIX Which Is the Better Value Stock Right Now | 09/24/2025 |
| Begin Period Cash Flow | 259.1 M | |
| Total Cashflows From Investing Activities | -126.8 M |
Neurocrine | Build AI portfolio with Neurocrine Stock |
Neurocrine Biosciences Relative Risk vs. Return Landscape
If you would invest 12,569 in Neurocrine Biosciences on June 29, 2025 and sell it today you would earn a total of 1,631 from holding Neurocrine Biosciences or generate 12.98% return on investment over 90 days. Neurocrine Biosciences is currently generating 0.209% in daily expected returns and assumes 1.7469% risk (volatility on return distribution) over the 90 days horizon. In different words, 15% of stocks are less volatile than Neurocrine, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neurocrine Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neurocrine Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neurocrine Biosciences, and traders can use it to determine the average amount a Neurocrine Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1197
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NBIX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.75 actual daily | 15 85% of assets are more volatile |
Expected Return
| 0.21 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Neurocrine Biosciences is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neurocrine Biosciences by adding it to a well-diversified portfolio.
Neurocrine Biosciences Fundamentals Growth
Neurocrine Stock prices reflect investors' perceptions of the future prospects and financial health of Neurocrine Biosciences, and Neurocrine Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neurocrine Stock performance.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0867 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 13.44 B | ||||
| Shares Outstanding | 99.18 M | ||||
| Price To Earning | 202.90 X | ||||
| Price To Book | 5.19 X | ||||
| Price To Sales | 5.61 X | ||||
| Revenue | 2.36 B | ||||
| Gross Profit | 1.58 B | ||||
| EBITDA | 639.7 M | ||||
| Net Income | 341.3 M | ||||
| Cash And Equivalents | 799.4 M | ||||
| Cash Per Share | 8.31 X | ||||
| Total Debt | 455.1 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 2.48 X | ||||
| Book Value Per Share | 27.21 X | ||||
| Cash Flow From Operations | 595.4 M | ||||
| Earnings Per Share | 3.38 X | ||||
| Market Capitalization | 14.08 B | ||||
| Total Asset | 3.72 B | ||||
| Retained Earnings | 29.2 M | ||||
| Working Capital | 1.22 B | ||||
| Current Asset | 384.07 M | ||||
| Current Liabilities | 25.71 M | ||||
About Neurocrine Biosciences Performance
Evaluating Neurocrine Biosciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Neurocrine Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Neurocrine Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 616.21 | 724.83 | |
| Return On Tangible Assets | 0.09 | 0.10 | |
| Return On Capital Employed | 0.18 | 0.19 | |
| Return On Assets | 0.09 | 0.10 | |
| Return On Equity | 0.13 | 0.14 |
Things to note about Neurocrine Biosciences performance evaluation
Checking the ongoing alerts about Neurocrine Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neurocrine Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neurocrine Biosciences has a strong financial position based on the latest SEC filings | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: GRFS or NBIX Which Is the Better Value Stock Right Now |
- Analyzing Neurocrine Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neurocrine Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Neurocrine Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neurocrine Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neurocrine Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neurocrine Biosciences' stock. These opinions can provide insight into Neurocrine Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.